Blood Podcast cover image

Pembrolizumab in PMBCL, allogeneic CD19 CAR T cells for pediatric B-cell ALL, and fetal iron overload in β-thalassemia

Blood Podcast

00:00

Pembrolizumab and PMBCL

Pembrolizumab was evaluated in a Phase 1B trial, including patients with relapsed or refractory PMBCL. The overall response rate, or OR, was 41%, with mainly grade 1 to 2 adverse events and no toxicity-related treatment discontinuations. Nivolumab also has relevant Phase 2 data in relapsed/refractor PMBCL but in combination with Brentoxamab vidoten.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app